Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

Fig 5

IL therapy with PV-10 in combination with anti-PD-1 antibodies leads to delayed growth of bystander M05 tumors.

Mice received 3x105 M05 tumor cells SC on bilateral flanks on Day 0. On Day 7, right flank tumors were injected with 50 μl PV-10 or PBS IL. Mice received 300 μg anti-PD-1 and NrIgG antibodies beginning on Day 8 and continuing 2x/week until mice had reached endpoint. Tumor growth was measured in (left panel) tumors treated with IL PBS or PV-10 and (right panel) untreated, bystander tumors. Each line represents the growth of tumor in a single mouse (n = 5–6 mice per treatment group).

Fig 5